This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Biogen (BIIB) Down on Report of Death in Alzheimer's Study
by Zacks Equity Research
Investor confidence in Biogen (BIIB) is rattled following reports of a study participant's death who was administered its Alzheimer's disease (AD) antibody in clinical studies.
Sarepta's (SRPT) DMD Gene Therapy BLA Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts Sarepta's (SRPT) regulatory filing seeking accelerated approval for SRP-9001, a gene therapy for DMD indication. A final decision is expected by May 2023.
Here's What's Driving AbbVie's (ABBV) Outperformance This Year
by Zacks Equity Research
AbbVie (ABBV) boasts several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.
Halozyme (HALO) Stock Rises 35% in the Year so Far: Here's Why
by Zacks Equity Research
Halozyme (HALO) is gaining on its proprietary drug delivery technology, ENHANZE. It expects strong revenues on the back of robust demand for its new partnered drugs.
Novartis (NVS) Set to Advance Malaria Drug Into Phase III
by Zacks Equity Research
Novartis (NVS) plans to advance ganaplacide/lumefantrine into a phase III study for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.
Pharma Stock Roundup: RHHBY's Alzheimer's Study Failure, EU Nod for SNY's Enjaymo
by Kinjel Shah
Roche's (RHHBY) late-stage Alzheimer's disease study on key pipeline candidate, gantenerumab fails. Sanofi's (SNY) Enjaymo to treat a rare form of anemia gets approval in Europe.
Novartis (NVS) Reportedly Looking to Sell Its Business Units
by Zacks Equity Research
Per a Bloomberg report, Novartis (NVS) is considering the sale of its ophthalmology and respiratory franchises.
Key Factors Driving Amgen's (AMGN) Outperformance This Year
by Zacks Equity Research
Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.
ImmunoGen (IMGN) Gets Accelerated FDA Approval for Ovarian Cancer Drug
by Zacks Equity Research
ImmunoGen (IMGN) receives accelerated FDA approval for its lead drug mirvetuximab soravtansine-gynx, to be marketed as Elahere. The drug will treat adults with ovarian cancer.
Roche (RHHBY) AD Study Failure Puts Spotlight on BIIB & Others
by Zacks Equity Research
Roche's (RHHBY) gantenerumab study for early Alzheimer's disease (AD) fails and puts focus on other companies like BIIB, LLY and PRTA.
Halozyme's (HALO) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Halozyme's (HALO) earnings and revenues beat estimates for the third quarter of 2022.
Prothena's (PRTA) Q3 Earnings Miss, Revenues Decline Y/Y
by Zacks Equity Research
Prothena (PRTA) incurs a loss in the third quarter while revenues miss estimates.
Amgen (AMGN) Beats on Q3 Earnings & Sales, Tweaks 2022 View
by Zacks Equity Research
Amgen (AMGN) beats Q3 estimates for earnings and sales. It tightens previously issued revenue and adjusted earnings guidance ranges.
Sarepta (SRPT) Q3 Loss Wider-Than-Expected, Sales Lag Estimates
by Zacks Equity Research
Sarepta's (SRPT) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales. Shares decline in after-market trading post the announcement.
Regeneron (REGN) Q3 Earnings & Sales Beat on Eylea, Dupixent
by Zacks Equity Research
Regeneron (REGN) tops earnings and sales estimates for the third quarter, driven by its lead drug Eylea and profits from the asthma drug, Dupixent. However, earnings decline year over year.
Blueprint Medicines (BPMC) Q3 Earnings & Revenues Top Mark
by Zacks Equity Research
Blueprint Medicines' (BPMC) earnings and revenues trump estimates for the third quarter of 2022. The company lowers product revenue guidance for Ayvakit.
Seagen's (SGEN) Q3 Earnings Miss, Revenues Surpass Estimates
by Zacks Equity Research
Seagen (SGEN) reports a wider-than-expected loss in the third quarter of 2022 while its revenues beat estimates. The company raises total revenue guidance for 2022.
Sesen Bio (SESN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Sesen Bio's (SESN) third-quarter earnings are likely to reflect the cost savings from the company's restructuring plans.
Will AbbVie's Immunology Drugs Continue to Drive Q3 Earnings?
by Zacks Equity Research
AbbVie's (ABBV) third-quarter performance is expected to reflect the impact of strong demand for immunology and aesthetics products.
Biogen (BIIB) Beats on Q3 Earnings & Sales, Raises 2022 Outlook
by Zacks Equity Research
Biogen (BIIB) beats third-quarter estimates for earnings and sales. Stock rises in pre-market as management raises the company's full-year 2022 financial guidance.
Novartis (NVS) Q3 Earnings Top, Revenues Miss Estimates
by Zacks Equity Research
Novartis (NVS) reports mixed results for the third quarter as key brands maintain momentum but generic competition remains a drag.
The Zacks Analyst Blog Highlights J&J, Roche, Eli Lilly and AbbVie
by Zacks Equity Research
J&J, Roche, Eli Lilly and AbbVie are part of The Zacks top Analyst Blog.
AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie (ABBV) third-quarter performance will likely reflect the impact of strong demand for immunology and aesthetics franchises. Investors will also enquire about ABBV's plans to counter Humira LOE.
Biogen (BIIB) to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
Biogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.
Pharma Stock Roundup: JNJ Q3 Earnings Beat, RHHBY Sales Weak, LLY, ABBV Ink M&A Deals
by Kinjel Shah
J&J (JNJ) beats earnings and sales estimates for the third quarter. Eli Lilly (LLY) and AbbVie (ABBV) announce small acquisitions.